Clozapine-treated Patients Have Marked Gastrointestinal Hypomotility, the Probable Basis of Life-threatening Gastrointestinal Complications: A Cross Sectional Study

EBioMedicine

Volumn 5, Issue , 2016, Pages 125-134

  Every Palmer, Susanna ^a,b   Nowitz, Mike ^b   Stanley, James ^b   Grant, Eve ^a   Huthwaite, Mark ^b   Dunn, Helen ^a   Ellis, Pete M ^b  

^a CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antipsychotic agents; Clozapine; Constipation; Gastrointestinal motility; Gastrointestinal tract; Laxatives

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; COLECALCIFEROL; HALOPERIDOL; LACTULOSE; MACROGOL; METFORMIN; NEUROLEPTIC AGENT; OLANZAPINE; OMEPRAZOLE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; COLON MOTILITY; CONSTIPATION; CROSS-SECTIONAL STUDY; DISTRESS SYNDROME; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; HUMAN; MALE; PRIORITY JOURNAL; RADIATION EXPOSURE; SCHIZOPHRENIA; SCINTIGRAPHY; STOMACH EMPTYING; ABDOMINAL RADIOGRAPHY; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM EXAMINATION; DOSE RESPONSE; DRUG EFFECTS; GASTROINTESTINAL TRACT; HOSPITAL PATIENT; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TIME FACTOR; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; CROSS-SECTIONAL STUDIES; DIAGNOSTIC TECHNIQUES, DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; INPATIENTS; MALE; MIDDLE AGED; RADIOGRAPHY, ABDOMINAL; TIME FACTORS; YOUNG ADULT;

EID: 84958581533     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.02.020     Document Type: Article

References (57)

1. Bailey L., Varma S., Ahmad N., Gee S., Taylor D.M. Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther. Adv. Psychopharmacol. 2015, 5:7.
2. Baptista T., Carrizo E., Fernandez E., et al. Colonic transit diagnostic test shows significant gastrointestinal hypomotility in clozapine-treated patients in comparison with subjects treated with other antipsychotics. Schizophr. Res. 2015, 166:4.
3. Bharucha A.E., Pemberton J.H., Locke G.R. American Gastroenterological Association technical review on constipation. Gastroenterology 2013, 144(1):218.
4. Bickerstaff L.K., Harris S.C., Leggett R.S., Cheah K.-C. Pain insensitivity in schizophrenic patients: a surgical dilemma. Arch. Surg. 1988, 123(1):49-51.
5. Bouchoucha M., Devroede G., Arhan P., et al. What is the meaning of colorectal transit time measurement?. Dis. Colon Rectum 1992, 35(8):773-782.
6. Caraceni A., Hanks G., Kaasa S., et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012, 13(2):e58-e68.
7. Carnahan R.M., Lund B.C., Perry P.J., Pollock B.G., Culp K.R. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J. Clin. Pharmacol. 2006, 46(12):1481-1486.
8. Chan Y.K., Kwan A.C.P., Yuen H., et al. Normal colon transit time in healthy Chinese adults in Hong Kong. J. Gastroenterol. Hepatol. 2004, 19(11):1270-1275.
9. Chaussade S., Roche H., Khyari A., Couturier D., Guerre J. Mesure du temps de transit colique (TTC): description et validation d'une nouvelle technique. Gastroenterol. Clin. Biol. 1986, 10(5):385-389.
10. Chew M.L., Mulsant B.H., Pollock B.G., et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 2006, 88(1):63-72.
11. Chew M.L., Mulsant B.H., Pollock B.G., et al. Anticholinergic activity of 107 medications commonly used by older adults. J. Am. Geriatr. Soc. 2008, 56(7):1333-1341.
12. Crowell M. The role of serotonin in the pathophysiology of irritable bowel syndrome. Am. J. Manag. Care 2001, 7(8 Suppl):S252.
13. De Hert M., Hudyana H., Dockx L., et al. Second-generation antipsychotics and constipation: a review of the literature. Eur. Psychiatry 2011, 26(1):34-44.
14. Dworkin R.H. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr. Bull. 1994, 20(2):235.
15. Every-Palmer S., Ellis P.M., Stanley J., Nowitz M., Dunn H., Huthwaite M., Grant E. Colonic transit studies to measure gastrointestinal motility in antipsychotic treated patients (protocol) 2013, Available at: http://hdl.handle.net/10523/6070.
16. Every-Palmer S., Newton-Howes G., Clarke M.J. Pharmacological Treatment for Antipsychotic-related Constipation 2014, Cochrane Library.
17. Fishbain D.A. Pain insensitivity in psychosis. Ann. Emerg. Med. 1982, 11(11):630-632.
18. Flanagan R.J., Ball R.Y. Gastrointestinal hypomotility: an under-recognised life-threatening adverse effect of clozapine. Forensic Sci. Int. 2011, 206(1-3):e31-e36.
19. Foxx-Orenstein A., McNally M., Odunsi S. Update on constipation: one treatment does not fit all. Cleve. Clin. J. Med. 2008, 75(11):813.
20. Frenchman I. Atypical antipsychotics for nursing home patients: a retrospective chart review. Drugs Aging 2005, 22(3):257.
21. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167(6):686-693.
22. Goodheart C.R., Leavitt S.B. Managing Opioid-induced Constipation in Ambulatory-care Patients 2006, 1-9. Pain Treatment Topics.
23. Graff J., Brinch K., Madsen J.L. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin. Physiol. 2001, 21(2):253-259.
24. Hayes G., Gibler B. Clozapine-induced constipation. Am. J. Psychiatry 1995, 152(2):298.
25. Hennen J., Baldessarini R.J. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 2005, 73(2):139-145.
26. Jung H.-K., Kim D.-Y., Moon I.-H. Effects of gender and menstrual cycle on colonic transit time in healthy subjects. Korean J. Intern. Med. 2003, 18(3):181-186.
27. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45(9):789-796.
28. Kelly D.L., Richardson C.M., Yu Y., Conley R.R. Plasma concentrations of high-dose olanzapine in a double-blind crossover study. Hum. Psychopharmacol. 2006, 21(6):393-398.
29. Kennedy J., Jeste D., Kaiser C., et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int. J. Geriatr. Psychiatry 2003, 18(11):1013.
30. Kim E.R., Rhee P.-L. How to interpret a functional or motility test-colon transit study. J. Neurogastroenterol. Motil. 2012, 18(1):94-99.
31. Kim J.E., Rhee P.L., Kim Y.H., et al. Clinical usefulness of KolomarkTM, a Korean radio-opaque marker for measuring colon transit time. Korean J. Med. 2001, 60(4):337-341.
32. Kim Y.H., Sim S.G., Cho K.R., et al. Colonic transit time in patient with liver cirrhosis [Korean]. Korean J. Gastroenterol. 2003, 42(5):394-399.
33. Lee O.Y. Asian motility studies in irritable bowel syndrome. J. Neurogastroenterol. Motil. 2010, 16(2):120.
34. Lee-Robichaud H., Thomas K., Morgan J., Nelson R.L. Lactulose Versus Polyethylene Glycol for Chronic Constipation 2010, The Cochrane Library.
35. Longstreth G.F., Thompson W.G., Chey W.D., Houghton L.A., Mearin F., Spiller R.C. Functional bowel disorders. Gastroenterology 2006, 130(5):1480-1491.
36. Mahassadi K., Ndri-Yoman T., Attia K., Ngbesso R., Keita A., Manlan K. Colonic transit time in healthy Ivorian subjects. Santé 2003, 13(4):265.
37. Meltzer H., Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am. J. Psychiatry 1995, 152(2):183.
38. Metcalf A.M., Phillips S.F., Zinsmeister A.R., MacCarty R.L., Beart R.W., Wolff B.G. Simplified assessment of segmental colonic transit. Gastroenterology 1987, 92(1):40-47.
39. Munro J., O'Sullivan D., Andrews C., Arana A., Mortimer A., Kerwin R. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br. J. Psychiatry 1999, 175:576.
40. Nguyen G.H., Brahmbhatt N., Heinrich T.W. A case report of clozapine-induced severe gastrointestinal hypomotility. Prim. Care Companion CNS Disord. 2014, 16(6).
41. Nielsen J., Meyer J.M. Risk factors for ileus in patients with schizophrenia. Schizophr. Bull. 2012, 38(3):592-598.
42. Ozbilen M., Adams C.E. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J. Clin. Psychopharmacol. 2009, 29(2):141-146.
43. Palmer S.E., McLean R.M., Ellis P.M., Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J. Clin. Psychiatry 2008, 69(5):759-768.
44. Pomerri F., Frigo A.C., Grigoletto F., Dodi G., Muzzio P.C. Error count of radiopaque markers in colonic segmental transit time study. AJR Am. J. Roentgenol. 2007, 189(2):W56-W59.
45. Rao S.S., Kuo B., McCallum R.W., et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin. Gastroenterol. Hepatol. 2009, 7(5):537-544.
46. Rao S., Camilleri M., Hasler W., et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European neurogastroenterology and motility societies. Neurogastroenterol. Motil. 2011, 23(1):8-23.
47. Remington G., Agid O., Foussias G., Ferguson L., McDonald K., Powell V. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?. Psychopharmacology 2013, 225(3):505-518.
48. Robertson G., Meshkinpour H., Vandenberg K., James N., Cohen A., Wilson A. Effects of exercise on total and segmental colon transit. J. Clin. Gastroenterol. 1993, 16(4):300-303.
49. Rosenthal S., Porter K., Coffey B. Pain insensitivity in schizophrenia. Case report and review of the literature. Gen. Hosp. Psychiatry 1990, 12(5):319.
50. Saad R.J., Rao S.S., Koch K.L., et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am. J. Gastroenterol. 2010, 105(2):403-411.
51. Singh M.K., Giles L.L., Nasrallah H.A. Pain insensitivity in schizophrenia: trait or state marker?. J. Psychiatr. Pract. 2006, 12(2):90-102. ®.
52. Sykes N., Fakata K., Yuan C.-S., et al. Handbook of Opioid Bowel Syndrome 2005, CRC Press.
53. Szarka L.A., Camilleri M. Methods for the assessment of small-bowel and colonic transit. Semin. Nucl. Med. 2012, 42(2):113-123.
54. Taylor D., Paton C., Kapur S. The Maudsley Prescribing Guidelines in Psychiatry 2015, John Wiley & Sons.
55. Twycross R., Sykes N., Mihalyo M., Wilcock A. Stimulant laxatives and opioid-induced constipation. J. Pain Symptom Manag. 2012, 43(2):306-313.
56. Walker A., Lanza L., Arellano F., Rothman K. Mortality in current and former users of clozapine. Epidemiology 1997, 8(6):671.
57. Wall B., Hart D. Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board. Br. J. Radiol. 1997, 70(833):437-439.